UNSPSC 51434821: Zolasartan

This classification denotes an angiotensin ii receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6NA6UHB9SW. European Medicines Agency schedules Zolasartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00174MIG. Zolasartan generally arises in the molecular formula C24H20BRCLN6O3.

UNSPSC 51434821 Zolasartan, a Commodity code, represents pharmaceutical active ingredients and finished medications that state and local governments procure for emergency medical services, public health programs, and institutional healthcare. Recent solicitations show state and local buyers acquiring specific medication line items — epinephrine, labetalol, adenosine, diltiazem, and related advanced life support drugs — through competitive bidding processes that emphasize firm pricing, expiration-date warranties, and rapid delivery cycles. The issuing bodies span city fire and rescue departments, state health agencies, and multistate cooperative purchasing alliances; the work involves direct supply of FDA-compliant pharmaceuticals with Safety Data Sheets and chain-of-custody documentation, often with options for contract renewal or extension.

Activity under this code concentrates in Florida and Minnesota, with significant state-level engagement in Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications to support Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000; the solicitation included a Small Local Business Enterprise sheltered-market 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 in January 2026 seeking generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling upstream interest in direct-contracting pharmacy models before formal competitive solicitation.